CompoAtlas

Saccharomyces boulardii

Natural health product licensed in Canada

Licence holder
Lallemand Health Solutions (Institut Rosell)
NPN or DIN-HM
80038395
Status
Active licence
Licence date
19 December 2012
Revision date
12 October 2022
Form
Poudre
Route of administration
Orale
Application type
Officinale

If this product were sold in France

No point flagged by the rules we apply.

A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.

Composition

Medicinal ingredient and sourcePer dosage unit, according to the sourceMaximum per day, adult
Saccharomyces boulardii

Source : En entier

5 Milliards d'UFCNot calculated

Non-medicinal ingredients

Maltodextrine

PopulationAgeQuantity per servingFrequency
Nourrissonsmaximum: 1 year1 packetminimum: 1 Tous les jours ; maximum: 2 Tous les jours
Adultesminimum: 18 years1 packet1 Tous les jours
Adultes, adolescents et enfantsminimum: 1 year2 packet1 Tous les jours

Uses authorised in Canada

Text supplied in English because no French text is available.

1 sachet per day: Probiotic to confer a health benefit. Per day provide live microorganisms to confer a health benefit. Provides intestinal comfort for travellers. Helps to reduce the risk of traveller's diarrhea. Source of probiotics. Could promote a favorable gut flora. Helps support gastrointestinal health. Helps support a healthy microbiome. 2 sachet per day: Helps reduce the risk of antibiotic associated diarrhea. Helps to prevent antibiotic associated diarrhea in adults. Helps to prevent antibiotic-associated diarrhea in children. Helps prevent antibiotic associated diarrhea. Helps to treat acute infectious diarrhea in children. Helps reduce the symptoms related to acute infectious diarrhea. An adjunct to physician-supervised antibiotic therapy in patients with Helicobacter pylori infections. An adjunct to physician-supervised antibiotic therapy in hospitalized patients with C. difficile infections/ Clostridium difficile Associated Diarrhea (CDAD) Help reduce the risk of AAD in hospitalized patients at risk of Clostridium difficile Associated Diarrhea (CDAD) Reduces the risk of recurrent C. difficile infection in conjunction with a physician supervised antibiotic therapy Help to reduce the risk of Clostridium difficile Associated Diarrhea (CDAD) when used as an adjunct to antibiotics (in hospitalized patients).

A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.

Warnings in Canada

No French warning text available in the imported data.

Warnings are available in English on the official record.

Source

Official Health Canada record, licence 80038395

Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.

Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)

Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)

The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.

List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).

List recorded in 2022. Photograph the packaging to check whether it has changed. Photograph the packaging

List recorded in 2022. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line